Grail, Inc. · NASDAQ:GRAL
Grail — ESMO Congress 2022
9 slides from Grail's conference presentation, September 2022
Slide 1: Time to Diagnosis Among Patients with Cancer in the US
Time to Diagnosis Among Patients with Cancer in the US Matthew Gitlin, PharmD Strategic Health Economics and Outcomes Research, BluePath Solutions Los Angeles, USA, September 2022
Slide 2: Declaration of Interests
DECLARATION OF INTERESTS Matthew Gitlin Consulting fees from *GRAIL LLC, a subsidiary of Illumina, Inc *currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October 2021. M.Gitlin Content of this presentation is copyright and re
Slide 3: Background
Background • Prior to cancer diagnosis, patients may present to a healthcare providers with unspecific signs and symptoms without a clear diagnosis pathway, which often leads to a lengthy diagnosis process, treatment delay, and high costs.1-3 • Multiple countries, including UK, Denmark, Sweden, Cana
Slide 4: Methods
Methods • A retrospective claims analysis of patients newly diagnosed with cancer in 2018-2019 was conducted using Optum’s de-identified Clinformatics® Data Mart Database including Medicare Advantage and commercially insured members from enrollees from a large private insurance plan in the US. • Mos
Slide 5: Results: Patient Selection and Baseline Characteristics
Results Patient Selection and Baseline Characteristics Optum Database Population (unique members, 1/1/2015-12/31/2019) All Cancers* N= 31,343,823 Characteristics N= 458,818 Not diagnosed with cancer Age, years Diagnosed with cancer per study methodology (2018-2019) N= 30,753,453 N= 590,370 mean (SD)
Slide 6: Results: Mean Time to Diagnosis
Results Mean Time to Diagnosis Uterus Thyroid Stomach Prostate Pancreas Ovarian Multiple Myeloma Lymphoma Lung Liver Leukemia Kidney Head and Neck Gallbladder Esophagus Colorectal Cervical Breast Bladder Anal All cancers -60 -40 -20 0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 3
Slide 7: Results: Percent of Cancer Patients with Time to Diagnosis >6 Months
Results Percent of Cancer Patients with Time to Diagnosis >6 Months Percent of Cancer Patients with Time to Diagnosis >6 Months 100% 90% 80% 70% 60% 52.8% 48.8% 50% 44.6% 46.1% 40% 31.9% 28.7% 30% 26.5% 24.8% 23.1% 21.9% 22.8% 20.1% 19.7% 16.7% 17.5% 15.4% 20% 14.3% 9.2% 10% 5.1% 4.6% 6.3% 0% Anal B
Slide 8: Conclusions
Conclusions • A notable proportion of patients newly diagnosed with cancer experienced a lengthy diagnosis process of > 6 months, highlighting the opportunity for increased inefficiency with regard to cancer diagnosis in the United States. • Large heterogeneity exists across cancer types and across
Slide 9: Thank you!
Thank you! European Society for Medical Oncology (ESMO) Via Ginevra 4, CH-6900 Lugano T. +41 (0)91 973 19 00 esmo@esmo.org esmo.org